Literature DB >> 11939268

Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.

Akihiko Gotoh1, Keisuke Miyazawa, Yoshiko Uchida, Goro Sashida, Ken Kawakubo, Yuzuru Kuriyama, Kazuma Ohyashiki.   

Abstract

We report a case of chronic myelogenous leukemia (CML) in which the bone marrow achieved cytogenetic complete remission (CCR) achieved by treatment with interferon-alpha and oral cytarabine ocfosfate after extramedullary blast crisis. A 51-year-old Japanese man diagnosed with CML was treated with interferon-alpha. Two months later; lymph node swellings developed in his neck and inguinal regions. Lymph node biopsy revealed the infiltration of blast cells showing bcr-abl fusion signal by fluorescence in situ hybridization analysis. Bone marrow aspiration and cytogenetic analysis demonstrated that his bone marrow was still in the chronic phase, with minor cytogenetic response. Continuing interferon-alpha for 6 months in combination with oral cytarabine ocfosfate resulted in the disappearance of the neck lymph node swellings followed by CCR in the bone marrow. However, rapid reenlargement of the neck and inguinal lymph nodes was noted 2 months after CCR despite maintaining medullary remission with major cytogenetic response. Finally, medullary crisis was noted 13 months from the initial development of the extramedullary crisis. This case suggests that interferon-alpha plus cytarabine ocfosfate therapy may be of benefit in the treatment of extramedullary blast crisis of CML.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939268     DOI: 10.1007/BF02982027

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  18 in total

1.  Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.

Authors:  H M Kantarjian; S O'Brien; T L Smith; M B Rios; J Cortes; M Beran; C Koller; F J Giles; M Andreeff; S Kornblau; S Giralt; M J Keating; M Talpaz
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

Review 2.  Lymph node metastases: the importance of the microenvironment.

Authors:  A D Santin
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

3.  Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease.

Authors:  T Terjanian; H Kantarjian; M Keating; M Talpaz; K McCredie; E J Freireich
Journal:  Cancer       Date:  1987-01-15       Impact factor: 6.860

Review 4.  Interaction of primitive human myeloid and lymphoid progenitors with the marrow microenvironment.

Authors:  P McGlave; C Verfaillie; J Miller
Journal:  Blood Cells       Date:  1994

5.  Lymphoid blast crisis during interferon-alpha therapy in a patient with chronic myelogenous leukemia in myeloid blast crisis.

Authors:  H Goto; H Tsurumi; T Hara; H Moriwaki
Journal:  Int J Hematol       Date:  2000-12       Impact factor: 2.490

Review 6.  The function of BCR/ABL and related proto-oncogenes.

Authors:  A Gotoh; H E Broxmeyer
Journal:  Curr Opin Hematol       Date:  1997-01       Impact factor: 3.284

7.  Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.

Authors:  S O'Brien; R Witt; M Talpaz; H Kantarjian
Journal:  Cancer       Date:  1991-04-01       Impact factor: 6.860

Review 8.  Extramedullary blast crisis in chronic myeloid leukemia.

Authors:  G Specchia; G Palumbo; D Pastore; D Mininni; A Mestice; V Liso
Journal:  Leuk Res       Date:  1996 Nov-Dec       Impact factor: 3.156

9.  Double P53 point mutation in extramedullary blast crisis of chronic myelogenous leukemia.

Authors:  R Marasca; G Longo; M Luppi; P Barozzi; G Torelli
Journal:  Leuk Lymphoma       Date:  1994-12

10.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

Authors:  J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

View more
  1 in total

1.  Chronic Myeloid Leukemia with Extramedullary Blast Crisis: Two Unusual Sites with Review of Literature.

Authors:  Kamal Kant Sahu; Pankaj Malhotra; Preithy Uthamalingam; Gaurav Prakash; Amanjit Bal; Neelam Varma; Subhash Chandar Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2014-10-29       Impact factor: 0.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.